175 related articles for article (PubMed ID: 37414394)
21. Dynamics of TIGIT and PD-1 expression on NK cells during the course of normal pregnancy.
Wang Y; Li D; Yu T; Hu M; Xing J; Bai S; Qu W; Tong X
Immunol Lett; 2021 Feb; 230():42-48. PubMed ID: 33359535
[TBL] [Abstract][Full Text] [Related]
22. TIGIT Signaling Pathway Regulates Natural Killer Cell Function in Chronic Hepatitis B Virus Infection.
Wang J; Hou H; Mao L; Wang F; Yu J; Luo Y; Lin Q; Sun Z
Front Med (Lausanne); 2021; 8():816474. PubMed ID: 35265633
[TBL] [Abstract][Full Text] [Related]
23. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
24. Combination Blockade of the IL6R/STAT-3 Axis with TIGIT and Its Impact on the Functional Activity of NK Cells against Prostate Cancer Cells.
González-Ochoa S; Tellez-Bañuelos MC; Méndez-Clemente AS; Bravo-Cuellar A; Hernández Flores G; Palafox-Mariscal LA; Haramati J; Pedraza-Brindis EJ; Sánchez-Reyes K; Ortiz-Lazareno PC
J Immunol Res; 2022; 2022():1810804. PubMed ID: 35465350
[TBL] [Abstract][Full Text] [Related]
25. Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy.
Zhou X; Li Y; Zhang X; Li B; Jin S; Wu M; Zhou X; Dong Q; Du J; Zhai W; Wu Y; Qiu L; Li G; Qi Y; Zhao W; Gao Y
Sci China Life Sci; 2024 May; 67(5):996-1009. PubMed ID: 38324132
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint markers and anti-CD20-mediated NK cell activation.
Wang Z; Weiner GJ
J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552
[TBL] [Abstract][Full Text] [Related]
27. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
[TBL] [Abstract][Full Text] [Related]
28. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
Front Immunol; 2021; 12():699895. PubMed ID: 34367161
[TBL] [Abstract][Full Text] [Related]
29. TIGIT-Fc Promotes Antitumor Immunity.
Shen X; Fu W; Wei Y; Zhu J; Yu Y; Lei C; Zhao J; Hu S
Cancer Immunol Res; 2021 Sep; 9(9):1088-1097. PubMed ID: 34244300
[TBL] [Abstract][Full Text] [Related]
30. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
Front Immunol; 2018; 9():2821. PubMed ID: 30555485
[TBL] [Abstract][Full Text] [Related]
31. Blocking TIGIT/CD155 signalling reverses CD8
Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
[TBL] [Abstract][Full Text] [Related]
32. Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia.
Xu LJ; Ma Q; Zhu J; Li J; Xue BX; Gao J; Sun CY; Zang YC; Zhou YB; Yang DR; Shan YX
Mol Med Rep; 2018 Jun; 17(6):8111-8120. PubMed ID: 29693186
[TBL] [Abstract][Full Text] [Related]
33. T-cell Ig and ITIM domain regulates natural killer cell activation in murine acute viral hepatitis.
Bi J; Zhang Q; Liang D; Xiong L; Wei H; Sun R; Tian Z
Hepatology; 2014 May; 59(5):1715-25. PubMed ID: 24319005
[TBL] [Abstract][Full Text] [Related]
34. Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT).
Bolm L; Petruch N; Sivakumar S; Annels NE; Frampton AE
J Clin Pathol; 2022 Apr; 75(4):217-221. PubMed ID: 35058314
[TBL] [Abstract][Full Text] [Related]
35. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions.
Esen F; Deniz G; Aktas EC
Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946
[TBL] [Abstract][Full Text] [Related]
36. A Crosstalk Between Castration-Resistant Prostate Cancer Cells, M2 Macrophages, and NK Cells: Role of the ATM-PI3K/AKT-PD-L1 Pathway.
Jin H; Zhu J; Xuan R; Zhou Y; Xue B; Yang D; Gao J; Zang Y; Xu L
Immunol Invest; 2023 Nov; 52(8):941-965. PubMed ID: 37732622
[TBL] [Abstract][Full Text] [Related]
37. Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence.
Ahmetlic F; Fauser J; Riedel T; Bauer V; Flessner C; Hömberg N; Hennel R; Brenner E; Lauber K; Röcken M; Mocikat R
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33441389
[TBL] [Abstract][Full Text] [Related]
38. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes.
Meng F; Li L; Lu F; Yue J; Liu Z; Zhang W; Fu R
Front Oncol; 2020; 10():1595. PubMed ID: 32903786
[TBL] [Abstract][Full Text] [Related]
40. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
Chen X; Xue L; Ding X; Zhang J; Jiang L; Liu S; Hou H; Jiang B; Cheng L; Zhu Q; Zhang L; Zhou X; Ma J; Liu Q; Li Y; Ren Z; Jiang B; Song X; Song J; Jin W; Wei M; Shen Z; Liu X; Wang L; Li K; Zhang T
Front Immunol; 2022; 13():828319. PubMed ID: 35273608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
